Who
James J. Ferguson III
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Mineralys Therapeutics; Chief Medical Officer, Cadrenal Therapeutics; Chief Medical Officer, Matinas Biopharma Holdings.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 25 Feb 2019
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —102,400 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —102,400 at $0.00 | filing |
| 5 Feb 2025filed 6 Feb 2025 | CVKD Cadrenal Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 15 Dec 2023filed 15 Dec 2023 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,200,000 at $0.00 | filing |
| 20 Dec 2022filed 22 Dec 2022 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —625,000 at $0.00 | filing |
| 14 Dec 2021filed 15 Dec 2021 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —587,600 at $0.00 | filing |
| 1 Jan 2021filed 4 Jan 2021 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —575,000 at $0.00 | filing |
| 17 Jun 2020filed 19 Jun 2020 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 1 Jan 2020filed 3 Jan 2020 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 25 Feb 2019filed 27 Feb 2019 | MTNB Matinas Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.